Recent Updates
Recently added Catalysts

Use Phase

Phase 3

Emergency Contraception | Small molecule | Other |Perrigo Company plc|Last Updated: Dec 2, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment1,270
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03208985A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC ConditionsPHASE3 COMPLETED 1,270May 23, 2017Jun 14, 2018Dec 2, 202234 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Proportion of Dosing Instances Among User Population Taken Within 120 Hours (5 Days) of Most Recent Episode of Unprotected Sex.
Up to 6 Weeks

The first primary endpoint is the proportion in which the denominator includes all dosing instances of the IP and the numerator includes all dosing instances of the IP which were taken within 120 hours (5 days) of the subject's most recent episode of unprotected sex.

Proportion of Dosing Instances Among User Population in Which no More Than One Tablet Was Taken.
Up to 6 Weeks

The second primary endpoint is the proportion in which the denominator is all discrete dosing instances of the IP and the numerator includes all dosing instances where no more than one tablet was taken.

Proportion of Female Selectors Who Are Not Pregnant at the Time of Selection Decision.
Day 1

The third primary endpoint is the proportion in which the denominator includes all females who selected to use the product (regardless of whether they purchased/used) and the numerator includes all female selectors who were not pregnant at the time of the selection decision.

Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeOTHER
Treatment Arms
ArmTypeDescription
Use Phase (Ulipristal Acetate, 30 mg)EXPERIMENTALOne tablet of 30 mg of ulipristal acetate for emergency contraception
Interventions
NameTypeDescription
Use Phase (Ulipristal Acetate, 30 mg)DRUGAll subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take 30 mg of ulipristal acetate. Subjects are to use the investigational product based on their understanding of the directions on the outer packaging including Drug Facts Label and inside the product packaging (in the Consumer Information Leaflet).
Unlock Study Design Details
Eligibility Criteria
SexFEMALE
Healthy VolunteersYes
Study Sites34

Inclusion Criteria: * Women who are self-pay or who are willing to be self-pay for the purposes of the study and who present for emergency contraception only for their own use Exclusion Criteria: * Cannot read, speak and understand English * Cannot see well enough to read information on the label

Countries:United States
Unlock Eligibility Criteria